Helsinn Group signs Exclusive Agreement with Purdue Pharma (Canada) for the Distribution and Licensing Rights of Aloxi® (palonosetron hydrochloride) in Canada

Helsinn Group signs Exclusive Agreement with Purdue Pharma (Canada) for the Distribution and Licensing Rights of Aloxi
^®
(palonosetron hydrochloride) in Canada

Lugano, Switzerland and Pickering, Canada, June 6, 2017 -
Helsinn Group and Purdue Pharma (Canada) today announce that they have signed a distribution and licence agreement granting Purdue Pharma (Canada) exclusive rights to distribute, promote, market and sell

ALOXI
^®

(palonosetron hydrochloride) in Canada.

ALOXI
^®

is an anti-emetic (5-HT
₃
receptor antagonist) authorized for sale by Health Canada in adults for the prevention of chemotherapy-induced nausea and vomiting (CINV)
ⁱ
.

ALOXI
^®

is approved in over 70 countries worldwide, including the United States, European countries and Japan.

Riccardo Braglia, Helsinn Group Vice Chairman and CEO,
commented:

"

ALOXI
^®

has helped to provide relief from CINV to patients across the world and, through this agreement with Purdue Pharma (Canada) we hope to extend its benefits to a greater number of patients in Canada. We are also pleased to be able to broaden our relationship with Purdue/Mundipharma Network, a trusted partner that we work with in many countries across 5 continents and look forward to working with them in Canada".

Dr. Craig Landau, Purdue Pharma (Canada) CEO
added:

"Patients deserve access to medicines and treatments that help them manage their symptoms so they can participate fully in the things that matter most to them Purdue Pharma (Canada) already offers medicines that benefit patients with cancer who also suffer from pain. Now, we can also help those who suffer from CINV.

ALOXI
^®

is a natural addition to our expanding portfolio."




ⁱ

http://purdue.ca/wp-content/uploads/2017/05/Aloxi-English-PM.pdf

                                                               END

About the Helsinn Group

Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland and the US, a representative office in China as well as a product presence in approximately 190 countries globally.

For more information, please visit
www.helsinn.com

About Purdue Pharma (Canada)

Purdue Pharma (Canada) is a research-based pharmaceutical company with its headquarters, R&D operations, and manufacturing located in Pickering, Ontario. The company is a leader in the research and development of medicines for the treatment of pain and central nervous system disorders (ADHD) and a growing pipeline of prescription and over the counter products. Privately held, Purdue Pharma (Canada) is independently associated with the worldwide Purdue/Napp/Mundipharma network of companies.

For more information, please visit our website
www.purdue.ca

For more information:

Helsinn Group Media Contact:

Paola Bonvicini

Group Head of Communication

Lugano, Switzerland

Tel: +41 (0) 91 985 21 21

Info-hhc@helsinn.com

• Please visit
  www.helsinn.com
• We are on Twitter. Follow us
  @HelsinnGroup

Purdue Pharma Canada:

Sarah Robertson, Director of Communications

Pickering, Ontario (CANADA)

media@purdue.ca